Diabetic Peripheral Neuropathy: Mechanisms and Emerging Therapies.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and emerging therapies without systematic search or meta-analytic methodology
PubMed 42117861 · doi:10.3390/biology15090723
What was done
This narrative review summarizes literature on the cellular and molecular mechanisms of diabetic peripheral neuropathy (DPN) in type 1 and type 2 diabetes mellitus. It synthesizes preclinical and clinical evidence on emerging disease-modifying interventions, including antioxidants, anti-inflammatory agents, mitochondrial modulators, amyloid oligomer modulators, neurotrophic enhancers, stem cell therapies, and gene therapies.
What was found
The abstract reports no numerical data. It notes that DPN pathogenesis involves metabolic pathway activation (polyol, hexosamine, protein kinase C), advanced glycation end-products, oxidative and mitochondrial stress, neurovascular deficits, dyslipidemia, and emerging contributors such as human islet amyloid polypeptide (hIAPP) toxicity. While several novel therapeutic classes show potential to alter disease progression in mechanistic or early human models, few have shown consistent benefits on objective measures of nerve structure or function in large clinical trials.
Why it matters
Current standard clinical management for DPN remains primarily symptomatic; this review maps the mechanistic targets and translational pipeline of candidate therapies intended to halt or reverse nerve damage.
Limits
The review relies on narrative synthesis rather than systematic review methodology or formal meta-analysis. The abstract provides no quantitative effect sizes, quality ratings of cited trials, or total study counts.
Cited by
- context Targeting mitochondria to increase their function can overcome the neurodegenerative process in peripheral neuropathy.